ClinicalTrials.gg
RecruitingNCT07626216Updated Nov 6, 2026

Impact of rTMS on Abnormal Cortical fMRI in Patients With Dystonia

An interventional study of Transcranial Magnetic Stimulation in Dystonia Disorder, sponsored by Northwell Health. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Northwell Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 6, 2026Primary outcomes revisedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 55 studies in Dystonic Disorders with a site in United States — 11 open to participants now, 13 under way, none of them phase 3. Dystonic Disorders · United States.

Planned enrollment
18th of 22
10 · median 19
Started
2026
with 1 other
No phase
5 of 55
4 open now
Primary completion
2028-05
later than 6 of 12 live
Registered
55th of 55
by date

Among the 55 studies in Dystonic Disorders with a site in United States, this one is the 18th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 55th registered.

Dystonic Disorders

95 studies on the registry are indexed under Dystonic Disorders; 19 are open to participants now.

Browse Dystonic Disorders studies →

Open to participants now

11 of the 55 studies in Dystonic Disorders with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Dystonic Disorders studies recruiting now, 4 (24%) set no upper age limit and 6 (35%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Dystonic Disorders with a site in United States, or all of them as a file.
02

Study summary

By tracking resting-state fMRI scans, we aim to discover how repetitive transcranial magnetic stimulation (rTMS) changes brain connectivity in individuals with dystonia.

Read the detailed description

Dystonia is a neurological movement disorder characterized by spontaneous involuntary muscle contractions that cause repetitive twisting motions. These involuntary movements affect various body regions, including the face (blepharospasm), jaw (bruxism, oromandibular dystonia), head and neck (torticollis), voice box (laryngeal spasm), hands (writer's cramp), or as multiple body segments simultaneously. Dystonia lacks defining neuropathological change, making diagnosis challenging, and rendering symptom management incomplete. Advanced imaging techniques, particularly spatial covariance analysis and graph theory computations have revealed insights into dystonia's underlying brain networks. This approach shows that the relative strength of the metabolic function at each brain region (called "hubs") regulates information flow within the network and between the network and the rest of the brain. The identification of accessible cortical hubs as integral parts of the dystonia network raises new therapeutic possibilities though non-invasive techniques. Continuous theta-burst stimulation (cTBS), a modified form of rTMS that mimics natural brain rhythms (theta 4-8Hz), can effectively inhibit the cortical hyperactivity in targeted hubs with shorter treatment times than traditional approaches. The rationale for this proposed pilot experiment is to combine advanced analysis of standard neuroimaging to refine target location for a test of whether the application of non-invasive rTMS (in the form of cTBS) modulates abnormal cortical regions or the entire brain network, or both, as these networks underlie dystonia.

Our PET investigations of patients with dystonia (DYT1 carriers both symptomatic and non-symptomatic) have identified hyperactive subcortical regions including the lentiform nuclei, cerebellum, and supplementary motor cortex. The dystonia-related brain metabolic networks that we generated with PET scanning, can now be generated with rs-fMRI, a less invasive technique that avoids radiation exposure and blood sampling. Graph Theory analysis indicates that the bilateral motor cortex (spanning the inter-hemispheric sulcus) and the left pre-motor region serve as critical hyperactive hubs. We hypothesize that modulating these hubs will disrupt the information flow in patients with dystonia. Using frameless stereotaxic optical system (Polaris Vicra, BrainSight 2.2), we can precisely target these cortical hubs with cTBS, the inhibitory form of rTMS.

We are encouraged by recent studies that showed that a single cTBS run (40sec) precisely targeted significantly modified brain networks in patients with dystonia.

Ameliorating dystonia has been one of the most controversial and challenging topics in treating hyperkinetic movement disorders, because it is difficult to estimate the overall whole brain responses after focal alterations caused by brain stimulation techniques. Our approach offers several innovations:

  1. Enhanced and personalized hypermetabolic cortical hub identification.
  2. Use of independent component analysis and graph theory to optimize location for cTBS delivery.
  3. Individual response to the single cTBS stimulation site will be used for customized modeling of the TMS effect.

Although previous attempts to use TMS to improve dystonia have been inconsistent, our precisely targeted approach may improve outcomes. Success with this method could expand TMS application beyond its established use in depression to other neurological disorders. The shift from PET to rs-fMRI for network mapping represents a significant advance, making the technique/treatment more accessible and easier on patients.

03

Conditions studied

  • Dystonia Disorder

Keywords

  • Transcranial Magnetic Stimulation, Hyperkinetic Movement Disorder,Truncal (Axial) Dystonia, Abnormal Posture,Contractions of the chest, back,abdominal muscles
04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • 18 and 80 years of age.
  • Patients who manifest dystonia - sustained involuntary movement of the head, neck, trunk or limbs.
  • The dystonia may be spontaneous or genetic, specifically DYT1 or DYT6 and then only those patients who are demonstrating dystonia. The patient/subject will have a normal neurological exam except for dystonia.

Exclusion criteria

Exclusion Criteria:

  • Heredodegenerative dystonia of the type DYT8,9 or 10.
  • Past history of head trauma, stroke, epilepsy, demyelinating disease
  • Hypertension in excess of 160mmHg systolic and 90mmHg diastolic
  • Congestive heart failure
  • Diabetes
  • Past psychiatric conditions: e.g., depression
  • Systemic metabolic disease: e.g., Wilson's disease, progressive neurodegenerative disease (like supranuclear palsy or corticobasal ganglionic degeneration)
  • Magnetizable incorporated metal parts - like pacemakers
  • History or diagnosis of Parkinson's disease
  • Presence of myoclonus
  • No previous surgery for dystonia
  • Long term exposure to benzodiazepines, neuroleptics or anticonvulsants
  • No botulinum toxin within 12 weeks of baseline assessment and fMRI.
  • Moderate to severe cognitive impairment (judged by a minimental status of \<24.)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Active rTMS Arm

    We will investigate how repetitive transcranial magnetic stimulation (rTMS) affects brain networks in patients with dystonia by measuring changes in resting state-functional magnetic resonance images (rs-fMRI).

    Device: Transcranial Magnetic Stimulation

Interventions

  • DeviceTranscranial Magnetic Stimulation

    Continuous theta-burst stimulation (cTBS), a modified form of rTMS that mimics natural brain rhythms (theta 4-8Hz), can effectively inhibit the cortical hyperactivity in targeted hubs with shorter treatment times than traditional approaches. The rationale for this proposed pilot experiment is to combine advanced analysis of standard neuroimaging to refine target location for a test of whether the application of non-invasive rTMS (in the form of cTBS) modulates abnormal cortical regions or the entire brain network, or both, as these networks underlie dystonia. This pilot study will provide the basis for a controlled study to test the effectiveness and robustness of any positive influence that TMS might have on the patients' dystonia.

06

What researchers measure

Primary outcomes

  1. Evaluating rs-fMRI Changes Following rTMS Treatment

    The primary objective is to identify and modify replicable brain networks in dystonia patients using rs-fMRI. These networks reflect underlying disease processes, clinical symptomatology or both. The primary endpoint is change in the rs-fMRI derived network after rTMS treatment for two or four weeks, or both. We expect there to be changes at two and four weeks. We will then analyze the robustness of these changes in the repeat fMRI one week after treatment ends. Initially, identification and validation of the dystonia pattern from the resting state MRI will occur; it is a task with which we are familiar and is detailed in our recent manuscript.

    Time frame: 2 to 4 weeks.

  2. Evaluating clinical change

    We will use standard scales - the Burke-Fahn-Marsden dystonia rating scale and TWSTRS - to evaluate a clinical outcome

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Northwell Health/Feinstein Institutes
    Manhasset, New York 11030, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for May 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 4, 2026
StartActual
Mar 4, 2026
Primary completionEst.
May 2028
CompletionEst.
May 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedHeredodegenrativeHeredodegenerative dystonia of the type DYT8,9 or 10.
Oct 16, 2026
Primary outcomes
Revised in 2 updates
What changed on Oct 16, 2026
  • AddedEvaluating clinical changeTime frame: 6mo
What changed on Nov 6, 2026
  • Time frameEvaluating rs-fMRI Changes Following rTMS TreatmentTwo to four weeks. → 2 to 4 weeks.
  • Time frameEvaluating clinical change6mo → 6 months
across 2 updates, Oct 16, 2026 – Nov 6, 2026
Design
Early Phase 1→Not applicable
Oct 16, 2026
Show all 2 updates
  1. Nov 6, 2026
    Primary outcomes 2 time frame changed
    What changed in the outcomes
    • Time frameEvaluating rs-fMRI Changes Following rTMS TreatmentTwo to four weeks. → 2 to 4 weeks.
    • Time frameEvaluating clinical change6mo → 6 months
  2. Oct 16, 2026
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedHeredodegenrativeHeredodegenerative dystonia of the type DYT8,9 or 10.
    Primary outcomes 1 added
    What changed in the outcomes
    • AddedEvaluating clinical changeTime frame: 6mo
    Design Early Phase 1→Not applicable
    + 3 other changes: identifiers, oversight details and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07626216
Lead sponsor
Northwell Health
Responsible party
Bruce Volpe (Professor, Investigator, Northwell Health) — Principal investigator
First posted
Jun 4, 2026
Start date
Mar 4, 2026
Primary completion
May 2028 (estimated)
Completion
May 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Celina B Fernandez, MS
Contact
cfernandez14@northwell.edu
516-562-3646
Bruce T Volpe, MD
Contact
bvolpe1@northwell.edu
516-562-3384

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion